New genetic abnormalities and treatment response in acute lymphoblastic leukemia.
暂无分享,去创建一个
[1] W. Evans,et al. Inhibition of glycolysis modulates prednisolone resistance in acute lymphoblastic leukemia cells. , 2009, Blood.
[2] R. Pieters,et al. Molecular‐genetic insights in paediatric T‐cell acute lymphoblastic leukaemia , 2008, British journal of haematology.
[3] A. Hall,et al. Mutation of genes affecting the RAS pathway is common in childhood acute lymphoblastic leukemia. , 2008, Cancer research.
[4] S. Mustjoki,et al. Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia. , 2008, Blood.
[5] A. Ferrando,et al. NOTCH1 extracellular juxtamembrane expansion mutations in T-ALL. , 2008, Blood.
[6] J. Downing,et al. Failure of CDKN2A/B (INK4A/B-ARF)-mediated tumor suppression and resistance to targeted therapy in acute lymphoblastic leukemia induced by BCR-ABL. , 2008, Genes & development.
[7] E. Thiel,et al. Thymic adult T-cell acute lymphoblastic leukemia stratified in standard- and high-risk group by aberrant HOX11L2 expression: experience of the German multicenter ALL study group , 2008, Leukemia.
[8] Christopher B. Miller,et al. BCR–ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros , 2008, Nature.
[9] A. Ferrando,et al. The role of the PTEN/AKT Pathway in NOTCH1-induced leukemia , 2008, Cell cycle.
[10] R. Pieters,et al. Leukemia-associated NF1 inactivation in patients with pediatric T-ALL and AML lacking evidence for neurofibromatosis. , 2008, Blood.
[11] B. Johansson,et al. FLT3 mutations in a 10 year consecutive series of 177 childhood acute leukemias and their impact on global gene expression patterns , 2008, Genes, chromosomes & cancer.
[12] B. Johansson,et al. Mutations of FLT3, NRAS, KRAS, and PTPN11 are frequent and possibly mutually exclusive in high hyperdiploid childhood acute lymphoblastic leukemia , 2008, Genes, chromosomes & cancer.
[13] Christian Urban,et al. Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95. , 2007, Blood.
[14] Andrew P. Stubbs,et al. The recurrent SET-NUP214 fusion as a new HOXA activation mechanism in pediatric T-cell acute lymphoblastic leukemia. , 2007, Blood.
[15] R. Stam,et al. Prognostic significance of high-level FLT3 expression in MLL-rearranged infant acute lymphoblastic leukemia. , 2007, Blood.
[16] F. Sigaux,et al. p16INK4A tumor suppressor gene expression and CD3epsilon deficiency but not pre-TCR deficiency inhibit TAL1-linked T-lineage leukemogenesis. , 2007, Blood.
[17] Rob Pieters,et al. FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to γ-secretase inhibitors , 2007, The Journal of experimental medicine.
[18] A. Ferrando,et al. The SCFFBW7 ubiquitin ligase complex as a tumor suppressor in T cell leukemia , 2007, The Journal of experimental medicine.
[19] R. Pieters,et al. A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial , 2007, The Lancet.
[20] U. Lendahl,et al. The tumor suppressor gene hCDC4 is frequently mutated in human T-cell acute lymphoblastic leukemia with functional consequences for Notch signaling. , 2007, Cancer research.
[21] R. Pieters,et al. Microarray-based identification of new targets for specific therapies in pediatric leukemia. , 2007, Current Drug Targets.
[22] M. Busslinger,et al. Pax5: the guardian of B cell identity and function , 2007, Nature Immunology.
[23] J. Hehir-Kwa,et al. High-resolution genomic profiling of childhood ALL reveals novel recurrent genetic lesions affecting pathways involved in lymphocyte differentiation and cell cycle progression , 2007, Leukemia.
[24] Christopher B. Miller,et al. Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia , 2007, Nature.
[25] S. Richards,et al. Prognosis of children with acute lymphoblastic leukemia (ALL) and intrachromosomal amplification of chromosome 21 (iAMP21). , 2007, Blood.
[26] J. Aster,et al. The multifaceted role of Notch in cancer. , 2007, Current opinion in genetics & development.
[27] Yi Zhang,et al. Leukaemic transformation by CALM–AF10 involves upregulation of Hoxa5 by hDOT1L , 2006, Nature Cell Biology.
[28] M. Muckenthaler,et al. Activating NOTCH1 mutations predict favorable early treatment response and long-term outcome in childhood precursor T-cell lymphoblastic leukemia. , 2006, Blood.
[29] J. Aster,et al. A phase I clinical trial of the notch inhibitor MK-0752 in patients with T-cell acute lymphoblastic leukemia/lymphoma (T-ALL) and other leukemias. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] M. Bhasin,et al. p16Ink4a or p19Arf loss contributes to Tal1-induced leukemogenesis in mice , 2006, Oncogene.
[31] R. Pieters,et al. Incidence of additional genetic changes in the TEL and AML1 genes in DCOG and COALL-treated t(12;21)-positive pediatric ALL, and their relation with drug sensitivity and clinical outcome , 2006, Leukemia.
[32] C. Pui,et al. Treatment of acute lymphoblastic leukemia. , 2006, The New England journal of medicine.
[33] R. Stam,et al. Activating FLT3 mutations in CD4+/CD8- pediatric T-cell acute lymphoblastic leukemias. , 2005, Blood.
[34] E. Macintyre,et al. CALM-AF10+ T-ALL expression profiles are characterized by overexpression of HOXA and BMI1 oncogenes , 2005, Leukemia.
[35] S. Armstrong,et al. Targeting FLT3 in primary MLL-gene-rearranged infant acute lymphoblastic leukemia. , 2005, Blood.
[36] M. D. Boer,et al. CDKN2 deletions have no prognostic value in childhood precursor-B acute lymphoblastic leukaemia , 2005, Leukemia.
[37] F. Sigaux,et al. HOXA genes are included in genetic and biologic networks defining human acute T-cell leukemia (T-ALL). , 2005, Blood.
[38] Yi Zhang,et al. hDOT1L Links Histone Methylation to Leukemogenesis , 2005, Cell.
[39] M. Relling,et al. Identification of genes associated with chemotherapy crossresistance and treatment response in childhood acute lymphoblastic leukemia. , 2005, Cancer cell.
[40] P. Marynen,et al. A new recurrent inversion, inv(7)(p15q34), leads to transcriptional activation of HOXA10 and HOXA11 in a subset of T-cell acute lymphoblastic leukemias , 2005, Leukemia.
[41] Dario Campana,et al. FLT3 inhibition selectively kills childhood acute lymphoblastic leukemia cells with high levels of FLT3 expression. , 2005, Blood.
[42] M. Bernstein,et al. Imatinib mesylate (STI571) for treatment of children with Philadelphia chromosome-positive leukemia: results from a Children's Oncology Group phase 1 study. , 2004, Blood.
[43] Andrew P. Weng,et al. Activating Mutations of NOTCH1 in Human T Cell Acute Lymphoblastic Leukemia , 2004, Science.
[44] A. Ferrando,et al. Fusion of NUP214 to ABL1 on amplified episomes in T-cell acute lymphoblastic leukemia , 2004, Nature Genetics.
[45] Cheng Cheng,et al. Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment. , 2004, The New England journal of medicine.
[46] S. Armstrong,et al. FLT3 mutations in childhood acute lymphoblastic leukemia. , 2004, Blood.
[47] M. Caligiuri,et al. Prognostic importance of TLX1 (HOX11) oncogene expression in adults with T-cell acute lymphoblastic leukaemia , 2004, The Lancet.
[48] W. Kern,et al. Satelite Symposium V, Meet-the-Professor Sessions I and II, Main Sessions I-IX , 2004, Annals of Hematology.
[49] F. Speleman,et al. Clinical significance of HOX11L2 expression linked to t(5;14)(q35;q32), of HOX11 expression, and of SIL-TAL fusion in childhood T-cell malignancies: results of EORTC studies 58881 and 58951. , 2004, Blood.
[50] E. Macintyre,et al. CALM-AF10 is a common fusion transcript in T-ALL and is specific to the TCRγδ lineage , 2003 .
[51] S. Armstrong,et al. Gene expression signatures in MLL-rearranged T-lineage and B-precursor acute leukemias: dominance of HOX dysregulation. , 2003, Blood.
[52] Rob Pieters,et al. Inhibition of FLT3 in MLL. Validation of a therapeutic target identified by gene expression based classification. , 2003, Cancer cell.
[53] R. Pieters,et al. In vitro drug resistance profile of Philadelphia positive acute lymphoblastic leukemia is heterogeneous and related to age: a report of the Dutch and German Leukemia Study Groups. , 2002, Medical and pediatric oncology.
[54] E. Lander,et al. Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia. , 2002, Cancer cell.
[55] R. Pieters,et al. TEL/AML1 gene fusion is related to in vitro drug sensitivity for L-asparaginase in childhood acute lymphoblastic leukemia. , 2000, Blood.
[56] T. Hoang,et al. SCL and LMO1 alter thymocyte differentiation: inhibition of E2A-HEB function and pre-Tα chain expression , 2000, Nature Immunology.
[57] O. Eden,et al. Monosomy 20 as a pointer to dicentric (9;20) in acute lymphoblastic leukemia , 2000, Leukemia.
[58] Wan Ariffin Bin Abdullah,et al. Med Pediatr Oncol , 1999 .
[59] Y. Hayashi,et al. Alterations of the p53, p21, p16, p15 and RAS genes in childhood T-cell acute lymphoblastic leukemia. , 1999, Leukemia research.
[60] M. D. Boer,et al. Relation between age, immunophenotype and in vitro drug resistance in 395 children with acute lymphoblastic leukemia–implications for treatment of infants , 1998, Leukemia.
[61] M. Link,et al. Frequent and selective methylation of p15 and deletion of both p15 and p16 in T-cell acute lymphoblastic leukemia. , 1997, Cancer research.
[62] R. Pieters,et al. Favorable prognosis of hyperdiploid common acute lymphoblastic leukemia may be explained by sensitivity to antimetabolites and other drugs: results of an in vitro study. , 1995, Blood.
[63] J. Sklar,et al. Chromosomal translocations joining LCK and TCRB loci in human T cell leukemia , 1991, The Journal of experimental medicine.
[64] J. Sklar,et al. TAN-1, the human homolog of the Drosophila Notch gene, is broken by chromosomal translocations in T lymphoblastic neoplasms , 1991, Cell.
[65] J. Meijerink,et al. Prognostic significance of molecular-cytogenetic abnormalities in pediatric T-ALL is not explained by immunophenotypic differences , 2008, Leukemia.
[66] A. Rolink,et al. PAX5/TEL acts as a transcriptional repressor causing down-modulation of CD19, enhances migration to CXCL12, and confers survival advantage in pre-BI cells. , 2008, Cancer research.
[67] W. Kamps,et al. The outcome of molecular-cytogenetic subgroups in pediatric T-cell acute lymphoblastic leukemia: a retrospective study of patients treated according to DCOG or COALL protocols. , 2006, Haematologica.
[68] P. Marynen,et al. Genetic insights in the pathogenesis of T-cell acute lymphoblastic leukemia. , 2005, Haematologica.
[69] W. Tissing,et al. Molecular determinants of glucocorticoid sensitivity and resistance in acute lymphoblastic leukemia , 2003, Leukemia.